Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax Reports Phase 2 Sub-Analysis of Hematide™ in Hemodialysis Patients
April 17th, 2009
Affymax, Inc. (Nasdaq:AFFY) announced data from a post hoc sub-analysis of the Phase 2 clinical trial evaluation of Hematide in chronic renal failure patients undergoing dialysis. These data suggest that Hematide maintains stable hemoglobin levels in hemodialysis patients for up to two years regardless of baseline iron (ferritin and transferrin saturation [TSAT]) or C-reactive protein (CRP) status, key factors in anemia of chronic kidney disease that often impact responsiveness to therapy with erythropoiesis stimulating agents (ESAs). Pablo Pergola, M.D., Ph.D. of Renal Associates in San Antonio Texas is the lead author of the poster, which was presented at the National...
Source: Health Business Week (2009-04-17)
|
